← Back to patent-cliff list
盐酸卡替洛尔/拉坦前列素
Tier C — Watch / tradeCarteolol Hydrochloride/Latanoprost
大冢制药株式会社
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：PTGFR、ADRB2、ADRB1
Brand：Mikeluna
Indications (approved)：高眼压、青光眼
Regional status
US
-
EU
-
China
临床三期
2022-09-27
Japan
批准上市
2016-09-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Carteolol Hydrochloride/Latanoprost?
Approved indications include: 高眼压, 青光眼.
When does the Carteolol Hydrochloride/Latanoprost patent expire?
No public expiry year is available for Carteolol Hydrochloride/Latanoprost yet; this page updates once verified.
How do I get a quote for Carteolol Hydrochloride/Latanoprost intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24